Evidence map›Paper›PMID 34603342›Full record

ReviewFrontiers in immunology2021

A Chaperone-Like Role for EBI3 in Collaboration With Calnexin Under Inflammatory Conditions.

Aruma Watanabe, Izuru Mizoguchi, Hideaki Hasegawa, Yasuhiro Katahira, Shinya Inoue, Eri Sakamoto, Yuma Furusaka, Ami Sekine, Satomi Miyakawa, Fumihiro Murakami and 3 more

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Aruma WatanabeDepartment of Immunoregulation, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan.
Izuru MizoguchiDepartment of Immunoregulation, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan.
Hideaki HasegawaDepartment of Immunoregulation, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan.
Yasuhiro KatahiraDepartment of Immunoregulation, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan.
Shinya InoueDepartment of Immunoregulation, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan.
Eri SakamotoDepartment of Immunoregulation, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan.
Yuma FurusakaDepartment of Immunoregulation, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan.
Ami SekineDepartment of Immunoregulation, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan.
Satomi MiyakawaDepartment of Immunoregulation, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan.
Fumihiro MurakamiDepartment of Immunoregulation, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan.
Mingli XuDepartment of Immunoregulation, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan.
Toshihiko YonetoDepartment of Immunoregulation, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan.
Takayuki YoshimotoDepartment of Immunoregulation, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan.
Tokyo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The interleukin-6 (IL-6)/IL-12 family of cytokines plays critical roles in the induction and regulation of innate and adaptive immune responses. Among the various cytokines, only this family has the unique characteristic of being composed of two distinct subunits, α- and β-subunits, which form a heterodimer with subunits that occur in other cytokines as well. Recently, we found a novel intracellular role for one of the α-subunits, Epstein-Barr virus-induced gene 3 (EBI3), in promoting the proper folding of target proteins and augmenting its expression at the protein level by binding to its target protein and a well-characterized lectin chaperone, calnexin, presumably through enhancing chaperone activity. Because calnexin is ubiquitously and constitutively expressed but EBI3 expression is inducible, these results could open an avenue to establish a new paradigm in which EBI3 plays an important role in further increasing the expression of target molecules at the protein level in collaboration with calnexin under inflammatory conditions. This theory well accounts for the heterodimer formation of EBI3 with p28, and probably with p35 and p19 to produce IL-27, IL-35, and IL-39, respectively. In line with this concept, another β-subunit, p40, plays a critical role in the assembly-induced proper folding of p35 and p19 to produce IL-12 and IL-23, respectively. Thus, chaperone-like activities in proper folding and maturation, which allow the secretion of biologically active heterodimeric cytokines, have recently been highlighted. This review summarizes the current understanding of chaperone-like activities of EBI3 to form heterodimers and other associations together with their possible biological implications.

Indexed as

CalnexinDimerizationGlycoproteinsHumansInflammationInterleukinsMembrane ProteinsMinor Histocompatibility AntigensMolecular ChaperonesNeoplasm ProteinsNeoplasmsProtein FoldingProtein Interaction MappingProtein SubunitsReceptors, InterleukinCalnexinCANX protein, humanEBI3 protein, humanGlycoproteinsIL23R protein, humanInterleukinsMembrane ProteinsMinor Histocompatibility AntigensMolecular ChaperonesNeoplasm ProteinsProtein SubunitsReceptors, InterleukincalnexinchaperoneEBI3heterodimertumor growth

Identifiers

PMID34603342
PMCPMC8484754
OpenAlexW3198954749

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.